“MOMENTUM Makes Mark,” goes the title of a note from HC Wainwright after positive Phase 3 trial results announced this morning.
The team now sees a 60% chance of approval for AXS-07, up from 30% previously, and lifts its price target to a Street-high $200 from $170. AXSM currently up 4.9% on the session to $106.99.
Presentation slides from this morning’s post-release conference call.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.